Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

References

• Bertino JR. Chemotherapy of colorectal cancer: History and new themes. Semin Oncol 1997; 24: S18–3–S18–7
   Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–47
   PubMed Web of Science ®Google Scholar
• De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Morton RF, Sargent DJ, et al. N9741: Oxaliplatin or CPT-11 plus 5-fluorouracil/leucovorin or oxaliplatin plus CPT-11 in advanced colorectal cancer. Updated efficacy and quality of life data from an intergroup study. Proc Am Soc Clin Oncol 2003;22:252 (abstr 1009).
   Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 2000; 355: 1041–7
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–14
   PubMed Web of Science ®Google Scholar
• Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Lancet 2000; 356: 373–8
   PubMed Web of Science ®Google Scholar
• Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 2005; 16: 425–9
   PubMed Web of Science ®Google Scholar
• Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61. Discussion 1061–4.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–14
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229–37
   PubMed Web of Science ®Google Scholar
• De Gramont A, Louvet C, André T, et al. A simplified bimonthly regimen with leucovorin and 5-fluorouracil for metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:287a (abstr 1019).
   Google Scholar
• Gil-Delgado MA, Bastian G, Guinet F, et al. Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol 2004; 27: 294–8
   PubMedGoogle Scholar
• Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21: 3761–9
   PubMed Web of Science ®Google Scholar
• Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003; 14: 481–9
   PubMed Web of Science ®Google Scholar
• Comella P, Casaretti R, De Rosa V, et al. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: A dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 2002; 13: 1874–81
   PubMedGoogle Scholar
• Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006–14
   PubMed Web of Science ®Google Scholar
• Souglakos J, Mavroudis D, Kakolyris S, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 2002; 20: 2651–7
   PubMed Web of Science ®Google Scholar
• Calvo E, Cortes J, Gonzalez-Cao M, et al. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer: A feasibility pilot study. Oncology 2002; 63: 254–65
   PubMedGoogle Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670–6
   PubMed Web of Science ®Google Scholar
• Abad A, Massuti B, Gallego J, et al. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. Anticancer Drugs 2004; 15: 469–71
   PubMedGoogle Scholar
• Abad A, Carrato A, Navarro M, et al. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high dose 5-fluorouracil as first line treatment for advanced colorectal cancer. Clin Colorectal Cancer 2005; 4: 384–9
   PubMedGoogle Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1
   PubMedGoogle Scholar
• Díaz-Rubio E, Aranda E, Camps C, et al. A phase II study of weekly 48-hour infusions with high-dose fluorouracil in advanced colorectal cancer: An alternative to biochemical modulation. J Infus Chemother 1994; 4: 58–61
   Google Scholar
• Aranda E, Cervantes A, Dorta J, et al. A phase II trial of weekly high-dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. Cancer 1995; 76: 559–63
   PubMedGoogle Scholar
• Díaz-Rubio E, Aranda E, Martín M, Gonzalez-Mancha R, Gonzalez-Larriba J, Barneto I. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26: 727–9
   PubMed Web of Science ®Google Scholar
• Aranda E, Carrato A, Cervantes A, et al. Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. Ann Oncol 2004; 15: 559–67
   PubMedGoogle Scholar
• Wasserman E, Cuvier C, Lokiec F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999; 17: 1751–9
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17: 902–6
   PubMed Web of Science ®Google Scholar
• Goldwasser F, Gross-Goupil M, Tigaud JM, et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 2000; 11: 1463–70
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002; 20: 165–72
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek GV, Ulrich-Pur H, et al. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma. Cancer 2001; 91: 1264–71
   PubMed Web of Science ®Google Scholar
• Quenet F, Nordlinger B, Riovire M, et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU(Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol 2004;23:273 (abstract 3613).
   Google Scholar
• De La Camara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 2004;23:268 (abstract 3591).
   Google Scholar
• Leonard G, Brenner B, Kemeny N. Neoadjuvant chemotherapy before live resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038–48
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvarth WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study. J Clin Oncol 2005; 23: 9243–9
   PubMed Web of Science ®Google Scholar
• Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 9063–90
   PubMedGoogle Scholar